<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;ACR Appropriateness Criteria&amp;reg; renal cell carcinoma staging.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Vikram R, Casalino DD, Remer EM, Arellano RS, Bishoff JT, Coursey CA, Dighe M, Eggli DF, Fulgham P, Israel GM, Lazarus E, Leyendecker JR, Nikolaidis P, Papanicolaou N, Ramchandani P, Sheth S, Expert Panel on Urologic Imaging. ACR Appropriateness CriteriaÂ® renal cell carcinoma staging. [online publication]. Reston (VA): American College of Radiology (ACR); 2011. 8 p.  [57 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Curry NS, Francis IR, Casalino DD, Arellano RS, Baumgarten DA, Dighe M, Fulgam P, Israel GM, Leyendecker JR, Papanicolaou N, Prasad S, Ramchandani P, Remer EM, Sheth S, Expert Panel on Urologic Imaging. ACR Appropriateness Criteria&amp;reg; renal cell carcinoma staging. [online publication]. Reston (VA): American College of Radiology (ACR); 2008. 8 p. [45 references]&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The appropriateness criteria are reviewed biennially and updated by the panels as needed, depending on introduction of new and highly significant scientific evidence.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Angiocardiography of venae cavae  (88.51); Arteriography of renal arteries  (88.45); Malignant neoplasm of kidney, except pelvis  (189.0)"/><FieldValue Value="MSH: Angiography ; Carcinoma, Renal Cell ; Contrast Media ; Diagnostic Imaging ; Fluorodeoxyglucose F18 ; Kidney Neoplasms ; Magnetic Resonance Angiography ; Magnetic Resonance Imaging ; Neoplasm Metastasis ; Neoplasm Staging ; Positron-Emission Tomography ; Radiography ; Radionuclide Imaging ; Technetium Compounds ; Tomography Scanners, X-Ray Computed ; Tomography, X-Ray Computed ; Ultrasonography ; Urography "/><FieldValue Value="MTH: angiogram ; Computed Tomography Scanning Systems ; Contrast Media ; Diagnostic Imaging ; Diagnostic Neoplasm Staging ; Diagnostic radiologic examination ; Fluorodeoxyglucose F18 ; Kidney Neoplasm ; Magnetic Resonance Angiography ; Magnetic Resonance Imaging ; Neoplasm Metastasis ; Plain chest X-ray ; Positron-Emission Tomography ; Radiographic imaging procedure ; Radionuclide Imaging ; Renal arteriography (procedure) ; Renal Cell Carcinoma ; Ultrasonography ; Urography ; X-Ray Computed Tomography "/><FieldValue Value="PDQ: angiography ; computed tomography ; diagnostic imaging ; diagnostic radiology ; fludeoxyglucose F 18 ; kidney tumor ; magnetic resonance imaging ; radionuclide imaging ; renal cell adenocarcinoma ; ultrasonography "/><FieldValue Value="SNOMEDCT_US: Angiography  (77343006); Arteriography  (129118002); Computerized axial tomography  (77477000); Contrast media  (385420005); Contrast media  (407935004); CT of abdomen with contrast  (32962002); Fluorodeoxyglucose F^18^  (35321007); Imaging  (363679005); Magnetic resonance imaging  (113091000); Magnetic resonance imaging  (312250003); Magnetic resonance imaging (MRI) of vessels  (241663008); Magnetic resonance imaging unit  (90003000); Neoplasm of kidney  (126880001); Nuclear medicine imaging procedure  (373205008); Plain chest X-ray  (399208008); Positron emission tomography  (363678002); Positron emission tomography  (82918005); Positron emission tomography unit  (39821008); Positron emission tomography unit  (462323006); Radiographic imaging procedure  (363680008); Radionuclide whole body bone study  (418832007); Renal arteriography  (79516005); Renal cell carcinoma  (41607009); Renal cell carcinoma  (702391001); Technetium compound  (47379009); Ultrasonography  (16310003); Ultrasonography  (278292003); Ultrasonography  (359659005); Ultrasonography of abdomen  (45036003); Venography of vena cava  (4438009)"/><FieldValue Value="SPN: SYSTEM, IMAGING, PULSED DOPPLER, ULTRASONIC ; SYSTEM, NUCLEAR MAGNETIC RESONANCE IMAGING ; SYSTEM, TOMOGRAPHY, COMPUTED, EMISSION ; SYSTEM, X-RAY, TOMOGRAPHY, COMPUTED "/><FieldValue Value="UMD: Contrast Media  (16-573); Radiographic Systems  (18-429); Scanning Systems, Computed Tomography  (13-469); Scanning Systems, Magnetic Resonance Imaging  (16-260); Scanning Systems, Positron Emission Tomography  (16-375); Scanning Systems, Ultrasonic  (14-278)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Renal cell carcinoma&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Nephrology" /><FieldValue Value="Nuclear Medicine" /><FieldValue Value="Oncology" /><FieldValue Value="Radiation Oncology" /><FieldValue Value="Radiology" /><FieldValue Value="Urology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Health Plans" /><FieldValue Value="Hospitals" /><FieldValue Value="Managed Care Organizations" /><FieldValue Value="Physicians" /><FieldValue Value="Utilization Management" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To evaluate the appropriateness of radiologic examinations in the staging of renal cell carcinoma&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adult patients with renal cell carcinoma&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;X-ray, chest &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Computed tomography (CT)&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Abdomen, without and with contrast &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Abdomen, with contrast &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Abdomen, without contrast &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Chest, without and with contrast &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Chest, with contrast &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Chest, without contrast &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Pelvis, without and with contrast&amp;nbsp; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Pelvis, with contrast &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Pelvis, without contrast &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Magnetic resonance imaging (MRI)&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Abdomen, without and with contrast &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Abdomen, without contrast &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Head, without and with contrast &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Head, without contrast &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ultrasound (US), abdomen &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Technetium (Tc)-99m bone scan, whole body &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fluorine-18-2-fluoro-2-deoxy-D-glucose - positron emission tomography (FDG-PET), skull base to mid-thigh &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Arteriography, kidney &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Utility of radiologic procedures in staging of renal cell carcinoma&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Literature Search Procedure&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Medline literature search is based on keywords provided by the topic author. The two general classes of keywords are those related to the condition (e.g., ankle pain, fever) and those that describe the diagnostic or therapeutic intervention of interest (e.g., mammography, MRI).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The search terms and parameters are manipulated to produce the most relevant, current evidence to address the American College of Radiology Appropriateness Criteria (ACR AC) topic being reviewed or developed. Combining the clinical conditions and diagnostic modalities or therapeutic procedures narrows the search to be relevant to the topic. Exploding the term &quot;diagnostic imaging&quot; captures relevant results for diagnostic topics.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The following criteria/limits are used in the searches.&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Articles that have abstracts available and are concerned with humans. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Restrict the search to the year prior to the last topic update or in some cases the author of the topic may specify which year range to use in the search. For new topics, the year range is restricted to the last 5 years unless the topic author provides other instructions. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;May restrict the search to Adults only or Pediatrics only. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Articles consisting of only summaries or case reports are often excluded from final results. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;The search strategy may be revised to improve the output as needed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The total number of source documents identified as the result of the literature search is not known.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Strength of Evidence Key&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Category 1 - The conclusions of the study are valid and strongly supported by study design, analysis, and results.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Category 2 - The conclusions of the study are likely valid, but study design does not permit certainty.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Category 3 - The conclusions of the study may be valid, but the evidence supporting the conclusions is inconclusive or equivocal.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Category 4 - The conclusions of the study may not be valid because the evidence may not be reliable given the study design or analysis.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Systematic Review with Evidence Tables" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The topic author drafts or revises the narrative text summarizing the evidence found in the literature. American College of Radiology (ACR) staff draft an evidence table based on the analysis of the selected literature. These tables rate the strength of the evidence for all articles included in the narrative text.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The expert panel reviews the narrative text, evidence table, and the supporting literature for each of the topic-variant combinations and assigns an appropriateness rating for each procedure listed in the table. Each individual panel member forms his/her own opinion based on his/her interpretation of the available evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;More information about the evidence table development process can be found in the ACR Appropriateness Criteria&amp;reg; Evidence Table Development document (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus (Delphi)" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Modified Delphi Technique&lt;/strong&gt; &lt;/p&gt;&#xD;&#xA;&lt;p&gt;The appropriateness ratings for each of the procedures included in the Appropriateness Criteria topics are determined using a modified Delphi methodology. A series of surveys are conducted to elicit each panelist's expert interpretation of the evidence, based on the available data, regarding the appropriateness of an imaging or therapeutic procedure for a specific clinical scenario. American College of Radiology (ACR) staff distributes surveys to the panelists along with the evidence table and narrative. Each panelist interprets the available evidence and rates each procedure. The surveys are completed by panelists without consulting other panelists. The ratings are a scale between 1 and 9, which is further divided into three categories: 1, 2, or 3 is defined as &quot;usually not appropriate&quot;; 4, 5, or 6 is defined as &quot;may be appropriate&quot;; and 7, 8, or 9 is defined as &quot;usually appropriate.&quot; Each panel member assigns one rating for each procedure per survey round. The surveys are collected and the results are tabulated, de-identified and redistributed after each round. A maximum of three rounds are conducted. The modified Delphi technique enables each panelist to express individual interpretations of the evidence and his or her expert opinion without excessive bias from fellow panelists in a simple, standardized and economical process.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Consensus among the panel members must be achieved to determine the final rating for each procedure. Consensus is defined as eighty percent (80%) agreement within a rating category. The final rating is determined by the median of all the ratings once consensus has been reached. Up to three rating rounds are conducted to achieve consensus.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If consensus is not reached, the panel is convened by conference call. The strengths and weaknesses of each imaging procedure that has not reached consensus are discussed and a final rating is proposed. If the panelists on the call agree, the rating is accepted as the panel's consensus. The document is circulated to all the panelists to make the final determination. If consensus cannot be reached on the call or when the document is circulated, &quot;No consensus&quot; appears in the rating column and the reasons for this decision are added to the comment sections.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline developers reviewed published cost analyses.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Criteria developed by the Expert Panels are reviewed by the American College of Radiology (ACR) Committee on Appropriateness Criteria.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;ACR Appropriateness Criteria&amp;reg;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Clinical Condition&lt;/span&gt;: Renal Cell Carcinoma Staging&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Variant 1&lt;/span&gt;: Tumor &amp;le;3 cm.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; summary=&quot;Table: Variant 1: Tumor less than or equal to 3 cm&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;bottom&quot; width=&quot;30%&quot; scope=&quot;col&quot;&gt;Radiologic Procedure&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;bottom&quot; width=&quot;20%&quot; scope=&quot;col&quot;&gt;Rating&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;bottom&quot; width=&quot;40%&quot; scope=&quot;col&quot;&gt;Comments&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;bottom&quot; width=&quot;25%&quot; scope=&quot;col&quot;&gt;RRL*&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CT abdomen without and with contrast&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;9&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Should include precontrast and postcontrast phases, including nephrographic phase. Multiplanar reconstructions and 3D volume-rendered images are helpful for surgical planning.&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CT abdomen with contrast &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;8 &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;X-ray chest &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;8&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Asymptomatic patient.&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;MRI abdomen without and with contrast&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;8&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;See statement regarding contrast in text under &quot;Anticipated Exceptions.&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;O&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;MRI abdomen without contrast &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;6&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;If iodinated and gadolinium base contrasts are contraindicated. &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;O&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CT chest without contrast&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;5&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Patient with solitary nodule on chest radiograph or respiratory symptoms.&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CT chest with contrast &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;5&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CT pelvis with contrast&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;4&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;US abdomen&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;4&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;More appropriate in patients with contrast sensitivity or renal insufficiency.&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;O&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CT abdomen without contrast&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CT chest without and with contrast&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CT pelvis without contrast&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CT pelvis without and with contrast&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;MRI head without and with contrast&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;O&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;MRI head without contrast&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;O&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;FDG-PET skull base to mid-thigh&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Attenuation correction by radionuclide methods or, more commonly, with computed tomography (CT) is considered part of the examination.&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Tc-99m bone scan whole body&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;    &lt;tfoot&gt;&#xD;&#xA;    &lt;tr&gt;&#xD;&#xA;        &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Rating Scale&lt;/span&gt;: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate&lt;/th&gt;&#xD;&#xA;        &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;*Relative Radiation Level&lt;/th&gt;&#xD;&#xA;    &lt;/tr&gt;&#xD;&#xA;    &lt;/tfoot&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;Note: Abbreviations used in the tables are listed at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Variant 2&lt;/span&gt;: Tumor &amp;gt;3 cm.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; summary=&quot;Table: Variant 2: Tumor greater than 3 cm&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;bottom&quot; width=&quot;30%&quot; scope=&quot;col&quot;&gt;Radiologic Procedure&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;bottom&quot; width=&quot;20%&quot; scope=&quot;col&quot;&gt;Rating&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;bottom&quot; width=&quot;40%&quot; scope=&quot;col&quot;&gt;Comments&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;bottom&quot; width=&quot;25%&quot; scope=&quot;col&quot;&gt;RRL*&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CT abdomen without and with contrast&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;9&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Should include precontrast and postcontrast, including nephrographic phase. Multiplanar reconstructions and 3D volume-rendered images are helpful for surgical planning.&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CT abdomen with contrast&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;8&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;X-ray chest&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;8&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CT chest without contrast&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;8&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Can identify subtle pulmonary nodules, mediastinal lymphadenopathy, bone and subcutaneous metastases. Confirms or excludes metastases seen on chest radiograph.&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CT chest with contrast &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;8&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;MRI abdomen without and with contrast&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;8&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;See statement regarding contrast in text under &quot;Anticipated Exceptions.&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;O&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;MRI abdomen without contrast&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;6&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;If iodinated and gadolinium base contrasts are contraindicated. &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;O&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CT pelvis with contrast &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;5&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;US abdomen&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;O&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Tc-99m bone scan whole body&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;More appropriate if tumor &amp;gt;7 cm or locally advanced; if bone pain present. Additional confirmatory imaging with radiographs, CT or MRI may be obtained if indicated.&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;MRI head without and with contrast&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp; &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;O&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;MRI head without contrast&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;O&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CT abdomen without contrast&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CT chest without and with contrast&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CT pelvis without contrast&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CT pelvis without and with contrast &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Arteriography kidney&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Appropriate as part of renal tumor embolization prior to surgery in hypervascular tumors to reduce blood loss at surgery and for palliation of hematuria in inoperable tumors. &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;FDG-PET skull base to mid-thigh&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Attenuation correction by radionuclide methods or, more commonly, with computed tomography (CT) is considered part of the examination.&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;    &lt;tfoot&gt;&#xD;&#xA;    &lt;tr&gt;&#xD;&#xA;        &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Rating Scale&lt;/span&gt;: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate&lt;/th&gt;&#xD;&#xA;        &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;*Relative Radiation Level&lt;/th&gt;&#xD;&#xA;    &lt;/tr&gt;&#xD;&#xA;    &lt;/tfoot&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;Note: Abbreviations used in the tables are listed at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Summary of Literature Review&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Renal cell carcinoma (RCC) accounts for 2% to 3% of all visceral malignancies. It is estimated that approximately 53,500 new cases of RCC are diagnosed per year in the U.S., resulting in approximately 13,040 deaths due to cancers of the kidney and renal pelvis. The incidence in men is 1.6 times greater than in women. Metastatic disease at presentation varies with the patient series but typically occurs in about one in 10 patients. The most common sites of distant metastases in descending order are the lung, bone, retroperitoneal and mediastinal nodes, liver, and brain, or in multiple sites.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Partial nephrectomy is now increasingly used in many patients with RCC. Radical nephrectomy, usually reserved for locally advanced RCC, involves node dissection and complete removal of the kidney and Gerota's fascia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Staging&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The traditional Robson system (see Appendix 1 in the original guideline document) used for staging renal cancers has significant limitations because it groups venous tumoral involvement and lymph node metastases in the same stage. In recent times, the TNM staging system (see Appendices 2 and 3 in the original guideline document) developed by the American Joint Committee on Cancer (AJCC) has become more commonly used and is regarded as more accurate and of greater prognostic value.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The TNM system, which was introduced in 1978, has been revised several times, most recently in 2010, to reflect evolving knowledge of the prognostic indicators over the decades. Significant changes from the 2002 version reflect the importance of tumor size, adrenal involvement, and the extent of renal vein involvement. Tumors between 7 cm and 10 cm are now classified as T2a lesions. Tumors &amp;gt;10 cm are now classified as T2b lesions. Tumors involving renal vein or its segmental branches (muscle-containing branches) are now reclassified as T3a. Tumors involving the inferior vena cava (IVC) below the diaphragm are considered T3b disease, whereas tumors involving the IVC above the diaphragm or invading the wall of the IVC are classified as T3c. Ipsilateral adrenal involvement is classified as T4 if the invasion is contiguous invasion and M1 if it is not contiguous. Nodal involvement is simplified to N0 versus N1. These changes reflect improved survival predictability over the previous versions of TNM staging.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Prior to the widespread use of ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI), patients with renal cancers were more likely to be symptomatic at discovery, and consequently the tumors were larger and of a higher stage, with approximately 33% of RCCs presenting in stage I, 10% in stage II, 25% in stage III, and 33% in stage IV. More recently, however, RCCs are increasingly discovered when they are small and therefore at lower stage. As many more tumors are identified serendipitously on cross-sectional imaging, a stage migration has been observed, with a greater proportion of newly diagnosed patients with RCC currently presenting with stage I disease. This trend is also associated with a decrease in the size of tumors in stage I RCCs. Based on the data of 31,233 kidney cancer patients from the National Cancer Data Base (NCDB) in the U.S. for the year 2007, the distribution of stage I, II, III and IV tumors was 60%, 10%, 14% and 16%, respectively, based on the 2002 TNM staging. With recent advancements in diagnosis and treatment, median 5-year cancer-specific survival rates have improved to 90%-95% for stage I, 75%-85% for stage II, 60%-70% for stage III, and 20%-30% for stage IV.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Prognosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Prognosis is related to several factors, including the tumor subtype, the size of the primary tumor, the stage, and the nuclear grade. In one large study evaluating 47,909 cases from the national cancer database, patients with tumors &amp;lt;4 cm in diameter had a 75% 5-year survival rate, whereas tumors &amp;gt;10 cm in diameter yielded a median survival rate of 47.5% at 5 years. Although incidentally discovered small tumors have a much better prognosis than symptomatic tumors, nonaggressive biologic behavior cannot be assumed. In one study of 50 lesions &amp;lt;3 cm in diameter, 38% had extension outside the renal capsule with T3/T4 disease. In another series, 12% of 318 T1 tumors had higher staging due to nodal and distant metastases which was likely related to other factors such as tumor subtype and nuclear grade.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Imaging in Staging&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Staging of Primary Tumor&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Preoperative imaging can provide important staging and anatomic information to the surgeon. Both CT and MRI are equally accurate in staging of the primary tumor. It is important to be aware that changes in pathologic stage of malignant renal neoplasms postoperatively are common, mainly due to changes seen in the size and renal sinus fat invasion on imaging studies. RCC is commonly multifocal. One of the important roles of preoperative imaging studies is also to look for synchronous primaries. Several studies have shown that both CT and US are suboptimal in detecting small synchronous primaries &amp;lt;1 cm in diameter, with detection rates ranging from 22% to 58%. However, an adequately designed CT protocol that includes the nephrographic phase appears to increase the detectability of small lesions.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Perinephric tumor extension (T3a) is difficult to discriminate from nonspecific perinephric stranding from edema, vascular engorgement, or fibrosis. High-resolution CT using thin sections appears to improve detection of perinephric infiltration, although false positives can be problematic. Breath-hold MRI showing lack of perinephric fat involvement is reported to have a high negative predictive value of no perinephric tumor invasion. A study of 73 RCCs showed that the presence of a pseudocapsule on MRI had an accuracy of 93% for clear-cell carcinomas in separating T1/T2 tumors from T3a tumors.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Renal sinus fat invasion, staged as T3a in the current TNM staging system, can be difficult to accurately detect on CT. It is considered as the most common site for extrarenal extension of RCC. The clinical significance of this finding is controversial. Several authors believe that the presence of renal sinus fat invasion heralds a poorer prognosis when compared to perinephric fat invasion. However, another group of researchers found no significant difference in outcomes. Nevertheless, presence of renal sinus fat invasion poses special challenges in planning nephron-sparing procedures and hence special caution should be taken when evaluating these structures. Many urologists rely on intraoperative frozen section, when available, to make these determinations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Direct contiguous spread to the adrenal, previously classified as T3a, now is classified as T4 in the latest TNM staging system. CT has a high sensitivity and nearly a 100% negative predictive value in detecting direct contiguous spread to the ipsilateral adrenal gland. However, the positive predictive value of CT is lower, as it may be difficult to distinguish abutment from direct invasion.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The extent of venous invasion of tumor is an important factor in the T staging in the current TNM staging system. Tumor extension into segmental branches or the main renal vein is seen in approximately 20% of cases and has been reclassified as T3a in light of recent evidence that this group of patients tends to have a better prognosis when compared to those with extension of tumor to the IVC, which is seen in up to 10% of patients. Not only must the involvement of the renal veins and IVC be identified, but the cephalic extent of the tumor must also be correctly assessed for preoperative planning. Depending on the level of an IVC thrombus, the surgeon may need to perform a thoracoabdominal incision instead of an abdominal incision. Intra-atrial thrombus may require cardiac bypass. Intrahepatic caval thrombus may require open thrombectomy or, if there is transmural invasion of the caval wall, a graft placement. Thrombus limited to the renal vein ostia may be &quot;milked&quot; back into the vein without the need to open the vein. Therefore, accurate assessment of caval thrombus is important. The prognostic significance of the extent of venous thrombus is still a topic of controversy, but recent evidence shows that supradiaphragmatic extension of IVC thrombus heralds a poorer prognosis than subdiaphragmatic extension.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Venous thrombus in the renal vein or IVC can usually be identified on the venous phase or delayed phase of the examination on the initial diagnostic CT. In cases where the findings are equivocal, MRI may be helpful. Tumor thrombus in the segmental branches of the renal vein may be more difficult to determine than thrombus in the main renal vein and IVC. Both contrast-enhanced multidetector CT and MRI have equal sensitivity in detecting venous involvement, particularly in the main renal vein and the IVC. Signs suggestive of renal vein or caval thrombus include filling defects, enlargement of the vessel, and rim enhancement. The pitfalls in CT occur with technically inadequate boluses of contrast media, motion, and flow artifact.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Due to its higher tissue contrast, noncontrast MRI has a higher sensitivity and specificity in detecting venous extension than a nonenhanced CT. Pitfalls of MRI include the potential for large tumors to compress the vena cava and flow-related artifacts. Such artifacts can be reduced with appropriate saturation pulses. With bright blood techniques, rapid or turbulent flow can also lead to artifacts. Diagnostic accuracy is improved with gadolinium-enhanced magnetic resonance (MR) venography. The highest sensitivity and specificity in assessing venous involvement are achieved with gradient echo sequence. Bland thrombus featuring low, uniform signal intensity and lack of enhancement after gadolinium can be distinguished from tumor thrombus, which exhibits intermediate or high signal intensity, heterogeneous intensity, and more reliably, the presence of small vessels. However, if a good-quality CT is obtained at several phases after contrast administration and the vein is clearly seen, MRI is usually not needed.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Venous anomalies should be sought, specifically the presence of a retroaortic left renal vein or circumaortic left renal vein, as these have surgical implications. CT and MR angiograms can be incorporated in any staging study to determine any arterial or venous anomalies that may be helpful in surgical planning. US and color duplex US may be used to study the venous invasion and venous anatomy, but this technique is of limited value in obese patients and in the presence of bowel gas, which interferes with the ability to image the renal vein-IVC junction. US is also highly dependent on the expertise of the operator.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Catheter angiography is insensitive for tumor thrombus. Its main roles are for preoperative embolization to reduce blood loss in hypervascular tumors and for palliation of hematuria in inoperable tumors.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Including the pelvis in routine staging examination is of limited value and is not likely to yield any significant results unless in rare instances of ectopic kidneys located in the pelvis. Two retrospective studies looking at a total of 519 staging CTs including both abdomen and pelvis reported that none of the pelvic CTs offered management altering information not already known to the clinical team.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Nodal Staging&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;As the current methodology for detecting lymph node metastases is based only on size, all imaging is suboptimal for N staging. Cross-sectional imaging criteria for diagnosing metastatic lymph nodes include a short axis diameter of &amp;gt;1 cm and disruption of the normal lymph node architecture. However, based on this criterion, CT has a false negative rate of about 10%, and nearly 50% of enlarged lymph nodes tend to be benign. MR lymphography with iron oxide nanoparticles shows promise, but the agent is not yet available in the United States. CT-guided aspiration biopsies are an alternative and can be performed if desired for documenting nodal metastases.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Contiguous invasion of the adrenal gland, liver, diaphragm, psoas muscles, pancreas, and bowel is seen in advanced T4 tumors and usually portends a poor prognosis. Both CT and MRI suffer with a poor positive predictive value, as it is occasionally difficult to distinguish mere abutment from invasion. However CT offers a high negative predictive value in excluding direct contiguous invasion.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Distant Metastases&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Distant metastases are commonly seen in lungs, bone, liver, and brain. Routine chest radiographs are considered necessary, but the routine use of chest CT is more controversial. For small primary lesions (&amp;lt;3 cm) the risk of metastases is small enough that the high cost and radiation of a chest CT may not be justified. The risk of pulmonary metastases increases with the size of the primary tumor, and although universally accepted guidelines do not yet exist, chest CT is justified for larger primary tumors. When the chest radiograph is suspicious or positive, chest CT is useful for confirming or excluding metastases and defining the extent of disease. Inclusion of CT scan of the pelvis with the abdomen rarely adds any valuable information. In a study of 119 patients undergoing preoperative CT staging, routine pelvic CT yielded no findings related to the RCC.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Neither routine bone scans nor bone surveys appear routinely justified. However, if the patient has an elevated alkaline phosphatase, bone pain, or an extremely large and aggressive tumor, bone scans may be helpful. Furthermore, use of brain MRI routinely cannot be justified, but it is indicated when neurologic symptoms are present, if the primary tumor is large, or if other metastatic disease is already present.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Positron emission tomography (PET) does not yet have an established role in staging renal cancer. Early studies using PET with the tracer fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG-PET) suggest that it may be difficult to even detect primary renal cancers against the normal background of high activity in the kidneys. PET may be helpful for establishing metastatic disease in lesions detected by CT, MRI, or bone scan, and it may be used to detect unsuspected metastases in high-risk patients. Although negative PET results cannot exclude metastatic disease, a positive PET scan should be considered highly suspicious for local recurrence or metastatic disease due its high specificity.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Summary&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Staging of renal cancer depends on the size of the primary tumor. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;For small or incidentally detected tumors (&amp;le;3 cm), multidetector, multiphasic CT of the abdomen with either CT of the chest or chest radiography is usually sufficient. MRI of the abdomen is a suitable substitute when the patient cannot undergo contrast-enhanced CT. Bone scan or MRI of the brain may be used in symptomatic patients. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;For larger primary tumors (&amp;gt;3 cm), multidetector, multiphasic CT of the abdomen with chest CT is the diagnostic modality of choice. If the status of the renal veins and IVC cannot be determined on CT, contrast-enhanced multiphasic three-dimensional (3D) MR venography should be performed. MRI of the abdomen is a suitable substitute for staging renal cancer when the patient cannot undergo contrast-enhanced CT. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prior to any major surgery to remove a locally advanced primary tumor, brain MRI and bone scan should be performed. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lesions detected by any modality that are suspicious for metastatic disease should be biopsied. FDG-PET scan may be considered as a noninvasive alternative. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;CTA and MRA could be incorporated into any staging study of the renal cancer to obtain information regarding the vascular supply, which can be helpful to surgeons in planning a resection. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Catheter angiography can be performed to embolize large tumors prior to resection &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Anticipated Exceptions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Nephrogenic systemic fibrosis (NSF) is a disorder with a scleroderma-like presentation and a spectrum of manifestations that can range from limited clinical sequelae to fatality. It appears to be related to both underlying severe renal dysfunction and the administration of gadolinium-based contrast agents. It has occurred primarily in patients on dialysis, rarely in patients with very limited glomerular filtration rate (GFR) (i.e., &amp;lt;30 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;), and almost never in other patients. There is growing literature regarding NSF. Although some controversy and lack of clarity remain, there is a consensus that it is advisable to avoid all gadolinium-based contrast agents in dialysis-dependent patients unless the possible benefits clearly outweigh the risk, and to limit the type and amount in patients with estimated GFR rates &amp;lt;30 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;. For more information, please see the American College of Radiology (ACR) Manual on Contrast Media (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Abbreviations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;3D, three-dimensional &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;CT, computed tomography &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;FDG-PET, fluorine-18-2-fluoro-2-deoxy-D-glucose - positron emission tomography &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;MRI, magnetic resonance imaging &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tc, technetium &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;US, ultrasound &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Relative Radiation Level Designations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Relative Radiation Level Definitions&quot; cellpadding=&quot;5&quot; width=&quot;50%&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Relative Radiation Level*&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Adult Effective Dose Estimate Range&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Pediatric Effective Dose Estimate Range&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;O&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;0 mSv&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;0 mSv&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&amp;lt;0.1 mSv&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&amp;lt;0.03 mSv&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;0.1-1 mSv&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;0.03-0.3 mSv&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1-10 mSv&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;0.3-3 mSv&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;10-30 mSv&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;3-10 mSv&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt; &lt;img alt=&quot;radioactive&quot; src=&quot;http://guideline.gov/images/image_radioactive.gif &quot; /&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;30-100 mSv&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;10-30 mSv&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;3&quot;&gt;*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (e.g., region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as NS (not specified).&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Algorithms were not developed from criteria guidelines.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The recommendations are based on analysis of the current literature and expert panel consensus.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Selection of appropriate radiologic imaging procedures for renal cell carcinoma staging&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Computed tomography (CT) has a false negative rate of about 10% in nodal staging.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Gadolinium-based Contrast Agents&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Nephrogenic systemic fibrosis (NSF) is a disorder with a scleroderma-like presentation and a spectrum of manifestations that can range from limited clinical sequelae to fatality. It appears to be related to both underlying severe renal dysfunction and the administration of gadolinium-based contrast agents. It has occurred primarily in patients on dialysis, rarely in patients with very limited glomerular filtration rate (GFR) (i.e., &amp;lt;30 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;), and almost never in other patients. Although some controversy and lack of clarity remain, there is a consensus that it is advisable to avoid all gadolinium-based contrast agents in dialysis-dependent patients unless the possible benefits clearly outweigh the risk, and to limit the type and amount in patients with estimated GFR rates &amp;lt;30 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;. For more information, please see the American College of Radiology (ACR) Manual on Contrast Media (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Relative Radiation Level (RRL)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, both because of organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared to those specified for adults. Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria&amp;reg; Radiation Dose Assessment Introduction document (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The American College of Radiology (ACR) Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists, and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the U.S. Food and Drug Administration (FDA) have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Vikram R, Casalino DD, Remer EM, Arellano RS, Bishoff JT, Coursey CA, Dighe M, Eggli DF, Fulgham P, Israel GM, Lazarus E, Leyendecker JR, Nikolaidis P, Papanicolaou N, Ramchandani P, Sheth S, Expert Panel on Urologic Imaging. ACR Appropriateness CriteriaÂ® renal cell carcinoma staging. [online publication]. Reston (VA): American College of Radiology (ACR); 2011. 8 p.  [57 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="1995 (revised 2011)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="American College of Radiology - Medical Specialty Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The American College of Radiology (ACR) provided the funding and the resources for these ACR Appropriateness Criteria&amp;reg;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Committee on Appropriateness Criteria, Expert Panel on Urologic Imaging&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Panel Members&lt;/em&gt;: Raghunandan Vikram, MD; David D. Casalino, MD (&lt;em&gt;Panel Chair&lt;/em&gt;); Erick M. Remer, MD (&lt;em&gt;Panel Vice-chair&lt;/em&gt;); Ronald S. Arellano, MD; Jay T. Bishoff, MD; Courtney A. Coursey, MD; Manjiri Dighe, MD; Douglas F. Eggli, MD; Pat Fulgham, MD; Gary M. Israel, MD; Elizabeth Lazarus, MD; John R. Leyendecker, MD; Paul Nikolaidis, MD; Nicholas Papanicolaou, MD; Parvati Ramchandani, MD; Sheila Sheth, MD.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Curry NS, Francis IR, Casalino DD, Arellano RS, Baumgarten DA, Dighe M, Fulgam P, Israel GM, Leyendecker JR, Papanicolaou N, Prasad S, Ramchandani P, Remer EM, Sheth S, Expert Panel on Urologic Imaging. ACR Appropriateness Criteria&amp;reg; renal cell carcinoma staging. [online publication]. Reston (VA): American College of Radiology (ACR); 2008. 8 p. [45 references]&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The appropriateness criteria are reviewed biennially and updated by the panels as needed, depending on introduction of new and highly significant scientific evidence.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;https://acsearch.acr.org/docs/69372/Narrative&quot; title=&quot;ACR Web site&quot;&gt;American College of Radiology (ACR) Web site&lt;/a&gt;.&lt;/p&gt;&#xA;&lt;p&gt;Print copies: Available from the American College of Radiology, 1891 Preston White Drive, Reston, VA 20191. Telephone: (703) 648-8900.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;ACR Appropriateness Criteria&amp;reg;. Overview. Reston (VA): American College of Radiology; 2 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.acr.org/~/media/ACR/Documents/AppCriteria/Overview.pdf&quot; title=&quot;ACR Web site&quot;&gt;American College of Radiology (ACR) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ACR Appropriateness Criteria&amp;reg;. Literature search process. Reston (VA): American College of Radiology; 1 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.acr.org/~/media/ACR/Documents/AppCriteria/LiteratureSearchProcess.pdf&quot; title=&quot;ACR Web site&quot;&gt;ACR Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ACR Appropriateness Criteria&amp;reg;. Evidence table development &amp;ndash; diagnostic studies. Reston (VA): American College of Radiology; 2013 Nov. 3 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.acr.org/~/media/ACR/Documents/AppCriteria/ETDevDiagnostic.pdf&quot; title=&quot;ACR Web site&quot;&gt;ACR Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ACR Appropriateness Criteria&amp;reg;. Radiation dose assessment introduction. Reston (VA): American College of Radiology; 2 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.acr.org/~/media/ACR/Documents/AppCriteria/RadiationDoseAssessmentIntro.pdf&quot; title=&quot;ACR Web site&quot;&gt;ACR Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ACR Appropriateness Criteria&amp;reg; Manual on contrast media. Reston (VA): American College of Radiology; 90 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.acr.org/Quality-Safety/Resources/Contrast-Manual&quot; title=&quot;ACR Web site&quot;&gt;ACR Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ACR Appropriateness Criteria&amp;reg; renal cell carcinoma staging. Evidence table. Reston (VA): American College of Radiology; 2011. 14 p. Electronic copies: Available from the &lt;a href=&quot;https://acsearch.acr.org/docs/69372/ET&quot; title=&quot;ACR Web site&quot;&gt;ACR Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This summary was completed by ECRI on May 6, 2001. The information was verified by the guideline developer on June 29, 2001. This summary was updated by ECRI on September 8, 2004. The updated information was verified by the guideline developer on October 8, 2004. This NGC summary was updated by ECRI on February 9, 2006. This NGC summary was updated by ECRI Institute on December 4, 2007. This NGC summary was updated by ECRI Institute on June 18, 2010. This summary was updated by ECRI Institute on January 13, 2011 following the U.S. Food and Drug Administration (FDA) advisory on gadolinium-based contrast agents. This NGC summary was updated by ECRI Institute on March 9, 2012.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Instructions for downloading, use, and reproduction of the American College of Radiology (ACR) Appropriateness Criteria&amp;reg; may be found on the &lt;a href=&quot;http://www.acr.org/Quality-Safety/Appropriateness-Criteria/TermsConditions&quot; title=&quot;ACR Web site&quot;&gt;ACR Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
